Targeted drugs available for colorectal cancer combined with liver metastasis include cetuximab. The most common metastatic organ of colorectal cancer is liver, which is also one of the main causes of death in advanced colorectal cancer. Bowel adenocarcinoma combined with liver metastasis indicates that the bowel cancer has entered the advanced stage, at this time, the chance of surgery has usually been lost, and comprehensive treatment is usually recommended. Targeted therapy drugs are mainly: 1. cetuximab is a human-mouse chimeric monoclonal antibody against EGFR, which is used in combination with chemotherapy for the treatment of metastatic colorectal cancer with wild-type of RAS gene. 2; 2. bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor receptor (VEGF), which has been shown to be effective in combination with chemotherapy as first-line treatment for liver metastasis of unresectable colorectal cancer; 3. regorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that blocks several pro-angiogenic VEGFRs, inhibits the activity of multiple kinases associated with tumorigenesis and the tumor microenvironment; 4. furaquintinib is also an oral tyrosine kinase inhibitor (TKI) that highly selectively inhibits three subtypes of VEGF receptors 1, 2 and 3. Furaquintinib can inhibit VEGF receptor phosphorylation, thereby inhibiting tumor angiogenesis and ultimately inhibiting tumor growth. It is recommended to go to regular hospitals for consultation and treatment, and follow the doctor’s instructions to cooperate with the treatment, so as not to delay the condition. Drug therapy has specific indications, dosage, and the possibility of adverse reactions, please strictly follow the doctor’s instructions, do not self-medication.